凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
莱茵生物(002166)公告正文

莱茵生物:2014年第三季度报告全文

公告日期 2014-10-30
股票简称:莱茵生物 股票代码:002166
                桂林莱茵生物科技股份有限公司 2014 年第三季度报告全文桂林莱茵生物科技股份有限公司
    2014 年第三季度报告
        2014 年 10 月
                                                   桂林莱茵生物科技股份有限公司 2014 年第三季度报告全文
                                  第一节 重要提示
    公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。
    所有董事均已出席了审议本次季报的董事会会议。
    公司负责人秦本军、主管会计工作负责人周庆伟及会计机构负责人(会计主管人员)张为鹏声明:保证季度报告中财务报表的真实、准确、完整。
                                                                桂林莱茵生物科技股份有限公司 2014 年第三季度报告全文
                              第二节 主要财务数据及股东变化一、主要会计数据和财务指标公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据□ 是 √ 否
                                       本报告期末                         上年度末                 本报告期末比上年度末增减
    总资产(元)                                 1,194,811,519.77               1,149,099,935.23                            3.98%归属于上市公司股东的净资产
                                              217,697,439.06                     197,199,526.77                        10.39%(元)
                                                        本报告期比上年同期                                 年初至报告期末比上
                                    本报告期                                       年初至报告期末
                                                                增减                                          年同期增减
    营业收入(元)                      132,927,721.04                     123.44%          317,279,573.87                 38.33%归属于上市公司股东的净利润
                                       5,511,938.43                    -56.86%           20,263,860.00                  9.76%(元)归属于上市公司股东的扣除非经
                                       5,070,130.89                    139.41%           14,735,254.45                230.42%常性损益的净利润(元)经营活动产生的现金流量净额
                                        --                       --                      45,908,439.06                141.61%(元)
    基本每股收益(元/股)                            0.04                  -60.00%                      0.16               14.29%
    稀释每股收益(元/股)                            0.04                  -60.00%                      0.16               14.29%
    加权平均净资产收益率                           2.56%                    -4.74%                    9.77%                 -0.94%非经常性损益项目和金额√ 适用 □ 不适用
                                                                                                                      单位:元
                           项目                                 年初至报告期期末金额                          说明
                                                                                                 主要系处置锦汇投资 20%股权
    非流动资产处置损益(包括已计提资产减值准备的冲销部分)                            3,424,823.00 产生的收益及处置固定资产损
                                                                                                 失。计入当期损益的政府补助(与企业业务密切相关,按照国家统
                                                                                  1,310,272.00一标准定额或定量享受的政府补助除外)
                                                                                                 系 BT 项目综合费用的利息收
    计入当期损益的对非金融企业收取的资金占用费                                         691,466.65
                                                                                                 入。
    除上述各项之外的其他营业外收入和支出                                                11,320.56
       少数股东权益影响额(税后)                                                   -90,723.34
    合计                                                                              5,528,605.55                 --
                                                          桂林莱茵生物科技股份有限公司 2014 年第三季度报告全文对公司根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义界定的非经常性损益项目,以及把《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目,应说明原因□ 适用 √ 不适用
    公司报告期不存在将根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义、列举的非经常性损益项目界定为经常性损益的项目的情形。二、报告期末股东总数及前十名股东持股情况表1、报告期末普通股股东总数及前十名普通股股东持股情况表
                                                                                                          单位:股
    报告期末普通股股东总数                                                                                     41,098
                                          前 10 名普通股股东持股情况
                                                                  持有有限售条件         质押或冻结情况
    股东名称            股东性质     持股比例      持股数量
                                                                    的股份数量       股份状态          数量
    秦本军              境内自然人            19.77%     25,613,504        19,210,128
    姚新德              境内自然人             8.71%     11,286,403         8,464,802 质押                 11,285,282
    蒋安明              境内自然人             2.39%      3,101,576中国工商银行-
    广发聚丰股票型      境内非国有法人         0.39%        499,986证券投资基金
    黎科弟              境内自然人             0.36%        460,744上海远盟投资管
                    境内非国有法人         0.27%        351,597理有限公司
    徐庆元              境内自然人             0.26%        342,585
    陈国胜              境内自然人             0.25%        322,101
    刘蕊                境内自然人             0.23%        300,000
    盛庆霞              境内自然人             0.23%        300,000
                                     前 10 名无限售条件普通股股东持股情况
                                                                                            股份种类
             股东名称                    持有无限售条件普通股股份数量
                                                                                     股份种类          数量
    秦本军                                                                  6,403,376 人民币普通股          6,403,376
    蒋安明                                                                  3,101,576 人民币普通股          3,101,576
    姚新德                                                                  2,821,601 人民币普通股          2,821,601中国工商银行-广发聚丰股票型证
                                                                         499,986 人民币普通股             499,986券投资基金
    黎科弟                                                                   460,744 人民币普通股             460,744
                                                           桂林莱茵生物科技股份有限公司 2014 年第三季度报告全文
    上海远盟投资管理有限公司                                                 351,597 人民币普通股          351,597
    徐庆元                                                                   342,585 人民币普通股          342,585
    陈国胜                                                                   322,101 人民币普通股          322,101
    刘蕊                                                                     300,000 人民币普通股          300,000
    盛庆霞                                                                   300,000 人民币普通股          300,000上述股东关联关系或一致行动的说 公司股东秦本军先生与蒋安明先生为兄弟关系,属于一致行动人,除上述关联关系以
    明                                 外,公司前 3 大股东之间不存在关联关系或一致行动,其他股东之间关系不详。前 10 名无限售条件普通股股东参与
                                报告期末,公司第 8 大股东陈国胜通过投资者信用账户持有 248,301 股公司股份。融资融券业务股东情况说明(如有)公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内是否进行约定购回交易□ 是 √ 否
    公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内未进行约定购回交易。2、报告期末优先股股东总数及前十名优先股股东持股情况表□ 适用 √ 不适用
                                                        桂林莱茵生物科技股份有限公司 2014 年第三季度报告全文
                                       第三节 重要事项一、报告期主要会计报表项目、财务指标发生变动的情况及原因√ 适用 □ 不适用
    1.资产负债表项目大幅度变动及原因:                          单位:元
       项目         期末余额         期初余额         增减比例                    变动原因
    货币资金             26,697,766.45    38,680,937.10      -30.98% 主要系报告期公司购置新工厂建设用地所
                                                                 有权及归还银行贷款增加所致。
    预付款项             14,874,186.08     6,092,676.36      144.13% 系报告期预付货款增加所致。
    其他应收款           25,567,786.62    95,486,290.25      -73.22% 主要系报告期收回锦汇公司欠款所致
    其他流动资产           147,085.25      5,474,230.58      -97.31% 系报告期增值税留底进项减少所致
    在建工程              3,839,796.00      188,037.00      1942.04% 系报告期新工厂前期筹建费用增加所致
    无形资产             23,238,045.01     1,030,422.71     2155.20% 系报告期购置新工厂建设用地所有权所致。
    短期借款             40,000,000.00   106,507,253.68      -62.44% 系报告期归还部分银行贷款所致。
    预收款项            121,592,901.99      578,487.70     20919.10% 主要系报告期莱茵投资收到BT项目1.2亿回
                                                                 购资金所致。
    应付职工薪酬           833,284.30      3,461,412.20      -75.93% 系报告期支付上年度绩效工资所致。
    应付利息               632,638.87      1,342,841.60      -52.89% 系报告期银行贷款总额减少,计提应付利息
                                                                 相应减少所致。
    其他应付款           11,260,074.08    17,599,108.13      -36.02% 主要系报告期归还暂借款所致。
    其他综合收益           -448,321.83      -682,374.12       34.30% 系报告期人民币汇率变动引起外币报表折
                                                                 算差额变动所致。
    未分配利润           -3,440,473.21   -23,704,333.21       85.49% 系报告期利润增加所致。
    2.利润表项目大幅度变动及原因                           单位:元
        项目         本期金额         上期金额        增减比例                    变动原因
    营业收入            317,279,573.87   229,369,220.20      38.33% 主要系报告期植物提取物销售额大幅增加
                                                                 所致。
    营业成本            239,770,904.76   176,280,983.74      36.02% 营业成本随着销售规模扩大而相应增加。
    营业税金及附加        1,628,967.40     3,926,670.21      -58.52% 主要系报告期BT项目取得营业税可抵扣项
                                                                 增加所致。
    投资收益              8,066,250.25    25,910,638.37      -68.87% 主要系上年同期处置子公司80%股权获得
                                                                 较多投资收益所致。
    营业外收入            1,345,773.87     6,517,152.52      -79.35% 主要系报告期收到政府补助较上年减少所
                                                                 致。
    营业外支出            1,111,218.31     2,973,801.93      -62.63% 主要系报告期处置固定资产损失所致。
    其他综合收益            234,052.29      -545,537.39     142.90% 系报告期人民币汇率变动引起外币报表折
                                                                 算差额变动所致。
                                                                   桂林莱茵生物科技股份有限公司 2014 年第三季度报告全文
    3.现金流量表项目大幅度变动及原因:                                 单位:元
        项目              本期金额           上期金额           增减比例                  变动原因
    经营活动产生的现金        45,908,439.06    -110,317,822.21         141.61% 主要系报告期植物提取业务销售回款增加
    流量净额                                                                   以及收到BT项目回购资金所致。
    投资活动产生的现金        -8,985,849.82      44,010,435.80        -120.42% 主要系报告期购置新工厂建设用地使用权
    流量净额                                                                   所致。
    筹资活动产生的现金       -49,075,967.50      46,653,469.58        -205.19% 主要系报告期归还银行贷款增加所致。流量净额二、重要事项进展情况及其影响和解决方案的分析说明√ 适用 □ 不适用
    1.关于与美国嘉吉公司的合作进展情况
    2011年11月4日,公司披露了《关于签订日常经营重大合同的公告》。公司及全资子公司LAYN USA与美国嘉吉股份有限公司营养健康事业部正式签订了一份关于甜菊糖最终产品的长期独家《外包加工及供应协议》。根据协议的相关约定,该协议已经自动续约2年至2015年11月1日止。2014年1-9月,公司与美国嘉吉公司执行订单总计约1,149.36万美元。
    2.关于BT项目的进展情况
    2011年8月30日,公司披露了《关于全资子公司桂林莱茵投资有限公司签订BT项目合同的公告》。截至2014年9月底,BT项目累计完成工程产值约4.8亿元。2014年1-9月,莱茵投资实现收入9,428.85万元,净利润1,184.93万元。目前,BT项目累计已经收到工程回购款2.5亿元。
    3.关于新厂建设用地的进展情况
    由于政府部门工作失误,造成公司竞得的临国用(2014)第3807号土地使用权中部分土地(约80亩)存在权属纠纷。为配合临桂新区的建设,尽快落实公司新厂建设项目用地问题,经公司第四届董事会第四次会议审议通过,公司同意撤销该土地使用权证,由政府收回该土地使用权。同时,公司已经缴纳的土地出让金及相关费用由政府予以返还或在后续新厂建设项目用地竞拍过程中扣除等方式解决。因土地交易及登记相关事宜引发的法律责任公司不予追究。
    目前,公司管理层正积极与政府部门协商,配合处理前述土地权属纠纷问题,同时加快落实项目用地范围内其他土地的供地程序,争取早日取得新厂建设项目用地。
               重要事项概述                              披露日期                        临时报告披露网站查询索引
                                                                                    巨潮资讯网(www.cninfo.com.cn),公
    BT 项目合同实施进展公告                   2014 年 10 月 11 日
                                                                                    告编号 2014-048。
                                                                                    巨潮资讯网(www.cninfo.com.cn),公
    关于同意撤销土地使用权证的公告            2014 年 10 月 16 日
                                                                                    告编号 2014-050。三、公司或持股 5%以上股东在报告期内发生或以前期间发生但持续到报告期内的承诺事项√ 适用 □ 不适用
        承诺事由                承诺方                       承诺内容                承诺时间    承诺期限    履行情况股改承诺收购报告书或权益变动报
                                                         桂林莱茵生物科技股份有限公司 2014 年第三季度报告全文告书中所作承诺资产重组时所作承诺
                                          本公司上市时,当时持有本公司
                                          5%以上股份的股东秦本军、姚新
                                          德、杨晓涛及蒋安明向本公司出具
                                          了《避免同业竞争承诺函》,承诺:
                                          "本人将不在中国境内外直接或间
                                          接从事或参与任何在商业上对股                             截至本公告
    首次公开发行或再融资时 秦本军、姚新德、 份公司构成竞争的业务或活动,或 2007 年 09 月               披露日,该承
                                                                                       长期履行
    所作承诺                 杨晓涛及蒋安明   拥有与股份公司存在竞争关系的 13 日                       诺正在履行
                                          任何经济实体、机构、经济组织的                           中。
                                          权益,或以其他任何形式取得该经
                                          济实体、机构、经济组织的控制权,
                                          或在该经济实体、机构、经济组织
                                          中担任高级管理人员或核心技术
                                          人员。"其他对公司中小股东所作承诺
    承诺是否及时履行         是四、对 2014 年度经营业绩的预计2014 年度预计的经营业绩情况:归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形
    2014 年度归属于上市公司股东的净利润变动幅度                      -36.14%     至                           -12.91%2014 年度归属于上市公司股东的净利润变动区间
                                                                    2,200    至                             3,000(万元)
    2013 年度归属于上市公司股东的净利润(万元)                                                               3,444.82
                                              公司预计 2014 年度植物提取业务销售收入与上年同期相比将有较大增
                                              长,但报告期低毛利产品占比较大,导致收入增长对业绩的影响程度有
                                              限;而本年度随着 BT 项目建设进度的推进,陆续有单位工程完成竣工业绩变动的原因说明
                                              验收并确认收益,对公司业绩产生较大影响。由于 2013 年度处置锦汇
                                              投资 80%股权产生较大的投资收益,因此公司预计 2014 年度归属于上
                                              市公司股东的净利润与 2013 年度相比将出现一定下滑。五、证券投资情况□ 适用 √ 不适用
    公司报告期不存在证券投资。持有其他上市公司股权情况的说明□ 适用 √ 不适用
                                                        桂林莱茵生物科技股份有限公司 2014 年第三季度报告全文
    公司报告期未持有其他上市公司股权。六、新颁布或修订的会计准则对公司合并财务报表的影响√ 适用 □ 不适用
    1、执行修订后《企业会计准则第2号——长期股权投资》的相关情况
    根据修订后的《企业会计准则第2号——长期股权投资》规定,公司对持有的不具有控制、共同控制、重大影响,且其公允价值不能可靠计量的股权投资,作为按成本计量的可供出售金融资产进行核算,不作为长期股权投资核算,并对其采用追溯调整法进行调整。
    本次具体调整如下:
         被投资单位    交易基本 2013年1月1日                         2013年12月31日
                         信息   归属于母公司       长期股权投资 可供出售金融资 归属于母公司
                                股东权益(+/-)          (+/-)        产(+/-)      股东权益
                                                                                   (+/-)
       广 西 兴 安 农 村 1.26%股权             0     -2,030,000.00      2,030,000.00                 0
       合作银行
       桂 林 银 行 股 份 1.43%股权             0    -24,000,000.00     24,000,000.00                 0
       有限公司
       桂林锦汇投资        注[1]               0    -13,563,640.00     13,563,640.00                 0
       有限公司
             合计           --                 0    -39,593,640.00     39,593,640.00                 0
    注[1]:2013年6月,本公司的子公司桂林莱茵投资有限公司与桂林彰泰实业集团有限公司签订股权转让协议,转让其持有的桂林锦汇投资有限公司80%的股权。股权转让后,本公司对桂林锦汇投资有限公司不再具有控制及重大影响,采用成本法核算。
    上述会计政策变更自2014年7月1日开始执行,仅对资产负债表中“可供出售金融资产”和“长期股权投资”两个报表项目金额产生影响,对本公司2013年度财务状况、经营成果及现金流量未产生影响。
    2、执行修订后《企业会计准则第30号——财务报表列报》的相关情况
    根据修订后的《企业会计准则第30号——财务报表列报》规定,外币报表折算差额原在所有者权益项目下单独列示,现转入其他综合收益项目列报。
    本次具体调整事项如下:
                    项目             2013年1月1日归属于母公司股 2013年12月31日归属于母公
                                              东权益(+/-)             司股东权益(+/-)
           外币报表折算差额                           +264,475.64                      +682,374.12
           其他综合收益                               -264,475.64                      -682,374.12
           合计                                                  0                              0
    上述会计政策变更自2014年7月1日开始执行,仅对资产负债表中“外币报表折算差额”和“其他综合收益”两个报表项目金额产生影响,对本公司2013年度财务状况、经营成果及现金流量未产生影响。
                                         桂林莱茵生物科技股份有限公司 2014 年第三季度报告全文
    3、其他情况
    除上述两项调整事项以外,财政部今年颁布或修订的相关准则对公司财务报表没有影响。
    4、特别说明
    上述调整事项系公司财务部门根据财政部今年颁布或修订的会计准则初步分析的结果,尚未经过审计机构审计,具体调整事项以公司经审计的2014年度报告为准。
                                                        桂林莱茵生物科技股份有限公司 2014 年第三季度报告全文
                                         第四节 财务报表一、财务报表1、合并资产负债表编制单位:桂林莱茵生物科技股份有限公司
                                                                                                     单位:元
                 项目                        期末余额                               期初余额流动资产:
    货币资金                                             26,697,766.45                          38,680,937.10
    结算备付金
    拆出资金
    以公允价值计量且其变动计入当期损益的金融资产
    应收票据                                                                                      100,000.00
    应收账款                                             61,261,020.25                          76,936,169.74
    预付款项                                             14,874,186.08                           6,092,676.36
    应收保费
    应收分保账款
    应收分保合同准备金
    应收利息                                              8,904,273.68                           8,212,807.03
    应收股利
    其他应收款                                           25,567,786.62                          95,486,290.25
    买入返售金融资产
    存货                                                579,703,833.95                         448,073,073.83
    划分为持有待售的资产
    一年内到期的非流动资产
    其他流动资产                                            147,085.25                           5,474,230.58
    流动资产合计                                            717,155,952.28                         679,056,184.89非流动资产:
    发放委托贷款及垫款
    可供出售金融资产                                     32,363,609.00                          39,593,640.00
    持有至到期投资
                                   桂林莱茵生物科技股份有限公司 2014 年第三季度报告全文
    长期应收款                       14,500,000.00                        11,500,000.00
    长期股权投资
    投资性房地产                    264,393,546.85                       267,671,113.39
    固定资产                        134,721,379.79                       145,130,202.48
    在建工程                          3,839,796.00                          188,037.00
    工程物资
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                         23,238,045.01                         1,030,422.71
    开发支出
    商誉
    长期待摊费用                        883,050.38                         1,214,194.30
    递延所得税资产                    3,716,140.46                         3,716,140.46
    其他非流动资产
    非流动资产合计                      477,655,567.49                       470,043,750.34
    资产总计                           1,194,811,519.77                    1,149,099,935.23流动负债:
    短期借款                         40,000,000.00                       106,507,253.68
    向中央银行借款
    吸收存款及同业存放
    拆入资金
    以公允价值计量且其变动计入当期损益的金融负债
    应付票据
    应付账款                        101,884,538.01                       111,795,931.20
    预收款项                        121,592,901.99                          578,487.70
    卖出回购金融资产款
    应付手续费及佣金
    应付职工薪酬                        833,284.30                         3,461,412.20
    应交税费                         10,087,035.37                         8,985,852.66
    应付利息                            632,638.87                         1,342,841.60
    应付股利
    其他应付款                       11,260,074.08                        17,599,108.13
                                                     桂林莱茵生物科技股份有限公司 2014 年第三季度报告全文
    应付分保账款
    保险合同准备金
    代理买卖证券款
    代理承销证券款
    划分为持有待售的负债
    一年内到期的非流动负债                          200,788,224.00                        212,145,887.43
    其他流动负债                                       5,711,616.92                         6,776,523.88
    流动负债合计                                         492,790,313.54                        469,193,298.48非流动负债:
    长期借款                                        285,000,000.00                        285,000,000.00
    应付债券
    长期应付款
    专项应付款                                      179,909,426.92                        179,909,426.92
    预计负债
    递延所得税负债                                    2,053,201.75                          2,053,201.75
    其他非流动负债                                   17,198,483.00                         15,568,483.00
    非流动负债合计                                       484,161,111.67                        482,531,111.67
    负债合计                                             976,951,425.21                        951,724,410.15所有者权益(或股东权益):
    实收资本(或股本)                              129,533,760.00                        129,533,760.00
    资本公积                                         83,217,530.86                         83,217,530.86
    减:库存股
    专项储备
    其他综合收益                                       -448,321.83                           -682,374.12
    盈余公积                                          8,834,943.24                          8,834,943.24
    一般风险准备
    未分配利润                                        -3,440,473.21                       -23,704,333.21
    归属于母公司所有者权益合计                           217,697,439.06                        197,199,526.77
    少数股东权益                                        162,655.50                           175,998.31
    所有者权益(或股东权益)合计                         217,860,094.56                        197,375,525.08负债和所有者权益(或股东权益)总
                                                    1,194,811,519.77                     1,149,099,935.23计
    法定代表人:秦本军                 主管会计工作负责人:周庆伟                    会计机构负责人:张为鹏
                                                    桂林莱茵生物科技股份有限公司 2014 年第三季度报告全文2、母公司资产负债表编制单位:桂林莱茵生物科技股份有限公司
                                                                                                 单位:元
                 项目                    期末余额                               期初余额流动资产:
    货币资金                                         14,145,350.90                          36,159,744.42
    以公允价值计量且其变动计入当期损益的金融资产
    应收票据                                                                                  100,000.00
    应收账款                                         52,693,151.29                          58,875,278.18
    预付款项                                          8,077,151.43                           3,005,500.75
    应收利息
    应收股利
    其他应收款                                       23,590,787.92                          26,391,110.16
    存货                                            164,954,897.80                         167,411,720.97
    划分为持有待售的资产
    一年内到期的非流动资产
    其他流动资产                                                                             4,891,738.33
    流动资产合计                                        263,461,339.34                         296,835,092.81非流动资产:
    可供出售金融资产                                 32,363,609.00                          38,896,115.62
    持有至到期投资
    长期应收款
    长期股权投资                                    118,154,924.59                         118,154,924.59
    投资性房地产                                    264,393,546.85                         267,671,113.39
    固定资产                                        130,625,355.12                         136,361,780.64
    在建工程                                          3,839,796.00                            188,037.00
    工程物资
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                                         23,083,959.61                            862,186.61
    开发支出
    商誉
                                   桂林莱茵生物科技股份有限公司 2014 年第三季度报告全文
    长期待摊费用
    递延所得税资产                   3,541,722.06                          3,541,722.06
    其他非流动资产
    非流动资产合计                     576,002,913.23                        565,675,879.91
    资产总计                           839,464,252.57                        862,510,972.72流动负债:
    短期借款                        20,000,000.00                         96,507,253.68
    以公允价值计量且其变动计入当期损益的金融负债
    应付票据
    应付账款                        26,974,973.96                         16,901,579.98
    预收款项                         1,592,901.99                           578,487.70
    应付职工薪酬                       428,985.23                          2,557,850.20
    应交税费                         1,011,381.31                          2,718,318.46
    应付利息                                                                391,486.63
    应付股利
    其他应付款                     311,626,408.08                        263,937,781.97
    划分为持有待售的负债
    一年内到期的非流动负债             788,224.00                         11,576,448.00
    其他流动负债
    流动负债合计                       362,422,874.57                        395,169,206.62非流动负债:
    长期借款                        85,000,000.00                         85,000,000.00
    应付债券
    长期应付款
    专项应付款                     179,909,426.92                        179,909,426.92
    预计负债
    递延所得税负债
    其他非流动负债                  17,198,483.00                         15,568,483.00
    非流动负债合计                     282,107,909.92                        280,477,909.92
    负债合计                           644,530,784.49                        675,647,116.54所有者权益(或股东权益):
    实收资本(或股本)             129,533,760.00                        129,533,760.00
    资本公积                        83,217,530.86                         83,217,530.86
                                                             桂林莱茵生物科技股份有限公司 2014 年第三季度报告全文
    减:库存股
    专项储备
    其他综合收益
    盈余公积                                                  8,834,943.24                           8,834,943.24
    一般风险准备
    未分配利润                                               -26,652,766.02                        -34,722,377.92
    所有者权益(或股东权益)合计                                 194,933,468.08                         186,863,856.18负债和所有者权益(或股东权益)总
                                                             839,464,252.57                         862,510,972.72计
    法定代表人:秦本军                       主管会计工作负责人:周庆伟                      会计机构负责人:张为鹏3、合并本报告期利润表编制单位:桂林莱茵生物科技股份有限公司
                                                                                                          单位:元
                  项目                            本期金额                               上期金额
    一、营业总收入                                               132,927,721.04                          59,490,566.00
    其中:营业收入                                          132,927,721.04                          59,490,566.00
          利息收入
          已赚保费
          手续费及佣金收入
    二、营业总成本                                               125,824,585.03                          71,555,168.53
    其中:营业成本                                          102,502,841.10                          49,645,697.78
          利息支出
          手续费及佣金支出
          退保金
          赔付支出净额
          提取保险合同准备金净额
          保单红利支出
          分保费用
          营业税金及附加                                       1,664,262.72                           1,307,660.14
          销售费用                                             3,665,086.21                           2,987,551.85
          管理费用                                             9,382,374.70                           8,202,923.95
          财务费用                                             8,610,020.30                           9,411,334.81
          资产减值损失                                                                                        0.00
                                                           桂林莱茵生物科技股份有限公司 2014 年第三季度报告全文
       加   :公允价值变动收益(损失以“-”号填列)
             投资收益(损失以“-”号
                                                                                                  25,659,303.24填列)
             其中:对联营企业和合营企业的投资收益
             汇兑收益(损失以“-”号填
                                                                                                    -523,347.43列)
    三、营业利润(亏损以“-”号填列)                           7,103,136.01                         13,071,353.28
       加   :营业外收入                                       284,001.87                          1,005,328.40
       减   :营业外支出                                        20,061.00                          1,303,562.89
             其中:非流动资产处置损失四、利润总额(亏损总额以“-”号填
                                                             7,367,076.88                         12,773,118.79列)
       减:所得税费用                                        1,859,656.12
    五、净利润(净亏损以“-”号填列)                           5,507,420.76                         12,773,118.79
       其中:被合并方在合并前实现的净利润
       归属于母公司所有者的净利润                            5,511,938.43                         12,777,155.20
       少数股东损益                                             -4,517.67                             -4,036.41
    六、每股收益:                                       --                                   --
       (一)基本每股收益                                             0.04                                 0.10
       (二)稀释每股收益                                             0.04                                 0.10
    七、其他综合收益                                              -140,062.68                           -103,776.42其中:以后会计期间不能重分类进损益的其他综合收益项目
         以后会计期间在满足规定条件
    时将重分类进损益的其他综合收益项                              -140,062.68                           -103,776.42目
    八、综合收益总额                                             5,367,358.08                         12,669,342.37
       归属于母公司所有者的综合收益
                                                             5,371,875.75                         12,673,378.78总额
       归属于少数股东的综合收益总额                             -4,517.67                             -4,036.41
    法定代表人:秦本军                       主管会计工作负责人:周庆伟                    会计机构负责人:张为鹏
                                                    桂林莱茵生物科技股份有限公司 2014 年第三季度报告全文4、母公司本报告期利润表编制单位:桂林莱茵生物科技股份有限公司
                                                                                                单位:元
                 项目                    本期金额                               上期金额
    一、营业收入                                         69,115,403.42                         45,807,291.00
       减:营业成本                                  59,091,606.31                         38,223,565.81
           营业税金及附加                               698,042.44                           154,985.84
           销售费用                                   2,142,615.91                          2,144,514.68
           管理费用                                   7,800,824.26                          5,546,418.60
           财务费用                                   2,698,915.50                          3,913,355.45
           资产减值损失
       加:公允价值变动收益(损失以“-”号填列)
           投资收益(损失以“-”号填列)
           其中:对联营企业和合营企业的投资收益
    二、营业利润(亏损以“-”号填列)                    -3,316,601.00                        -4,175,549.38
       加:营业外收入                                   284,001.87                          1,002,328.40
       减:营业外支出                                    20,061.00                          1,283,562.89
           其中:非流动资产处置损失三、利润总额(亏损总额以“-”号填
                                                      -3,052,660.13                        -4,456,783.87列)
       减:所得税费用
    四、净利润(净亏损以“-”号填列)                    -3,052,660.13                        -4,456,783.87
    五、每股收益:                              --                                     --
       (一)基本每股收益                                     -0.02                                -0.03
       (二)稀释每股收益                                     -0.02                                -0.03六、其他综合收益其中:以后会计期间不能重分类进损益的其他综合收益项目
         以后会计期间在满足规定条件时将重分类进损益的其他综合收益项目
    七、综合收益总额                                      -3,052,660.13                        -4,456,783.87
                                                             桂林莱茵生物科技股份有限公司 2014 年第三季度报告全文
    法定代表人:秦本军                       主管会计工作负责人:周庆伟                      会计机构负责人:张为鹏5、合并年初到报告期末利润表编制单位:桂林莱茵生物科技股份有限公司
                                                                                                          单位:元
                   项目                           本期金额                               上期金额
    一、营业总收入                                               317,279,573.87                         229,369,220.20
       其中:营业收入                                        317,279,573.87                         229,369,220.20
             利息收入
             已赚保费
             手续费及佣金收入
    二、营业总成本                                               302,591,208.33                         238,562,969.39
       其中:营业成本                                        239,770,904.76                         176,280,983.74
             利息支出
             手续费及佣金支出
             退保金
             赔付支出净额
             提取保险合同准备金净额
             保单红利支出
             分保费用
             营业税金及附加                                    1,628,967.40                           3,926,670.21
             销售费用                                         10,167,304.63                           9,240,370.04
             管理费用                                         27,686,089.44                          22,118,522.85
             财务费用                                         23,435,927.59                          27,007,216.27
             资产减值损失                                        -97,985.49                             -10,793.72
       加   :公允价值变动收益(损失以“-”号填列)
             投资收益(损失以“-”号
                                                               8,066,250.25                          25,910,638.37填列)
             其中:对联营企业和合营企业的投资收益
             汇兑收益(损失以“-”号填
                                                                                                     -1,810,498.24列)
    三、营业利润(亏损以“-”号填列)                            22,754,615.79                          14,906,390.94
       加   :营业外收入                                       1,345,773.87                           6,517,152.52
                                                             桂林莱茵生物科技股份有限公司 2014 年第三季度报告全文
       减   :营业外支出                                       1,111,218.31                           2,973,801.93
             其中:非流动资产处置损
                                                               1,087,037.00                              66,290.64失四、利润总额(亏损总额以“-”号填
                                                              22,989,171.35                          18,449,741.53列)
       减:所得税费用                                          2,738,654.16
    五、净利润(净亏损以“-”号填列)                            20,250,517.19                          18,449,741.53
       其中:被合并方在合并前实现的净利润
       归属于母公司所有者的净利润                             20,263,860.00                          18,462,617.27
       少数股东损益                                              -13,342.81                             -12,875.74
    六、每股收益:                                       --                                     --
       (一)基本每股收益                                              0.16                                   0.14
       (二)稀释每股收益                                              0.16                                   0.14
    七、其他综合收益                                                 234,052.29                            -545,537.39其中:以后会计期间不能重分类进损益的其他综合收益项目
         以后会计期间在满足规定条件
    时将重分类进损益的其他综合收益项                                 234,052.29                            -545,537.39目
    八、综合收益总额                                              20,484,569.48                          17,904,204.14
       归属于母公司所有者的综合收益
                                                              20,497,912.29                          17,917,079.88总额
       归属于少数股东的综合收益总额                              -13,342.81                             -12,875.74
    法定代表人:秦本军                       主管会计工作负责人:周庆伟                      会计机构负责人:张为鹏6、母公司年初到报告期末利润表编制单位:桂林莱茵生物科技股份有限公司
                                                                                                          单位:元
                  项目                            本期金额                               上期金额
    一、营业收入                                                 205,163,753.24                         141,964,452.62
       减:营业成本                                          168,040,709.76                         112,165,700.33
            营业税金及附加                                       698,070.00                            445,372.98
            销售费用                                           6,707,814.40                           6,255,107.88
            管理费用                                          23,420,516.68                          16,163,022.12
                                                             桂林莱茵生物科技股份有限公司 2014 年第三季度报告全文
           财务费用                                            7,831,119.46                          16,255,447.89
           资产减值损失                                          448,601.22                            154,639.49
       加:公允价值变动收益(损失以“-”号填列)
           投资收益(损失以“-”号填
                                                               8,763,774.63                            251,335.13列)
           其中:对联营企业和合营企业的投资收益
    二、营业利润(亏损以“-”号填列)                             6,780,696.35                          -9,223,502.94
       加:营业外收入                                          1,344,273.87                           6,514,152.52
       减:营业外支出                                             55,358.32                           1,350,210.90
           其中:非流动资产处置损失                               34,151.63                              66,290.64三、利润总额(亏损总额以“-”号填
                                                               8,069,611.90                          -4,059,561.32列)
       减:所得税费用
    四、净利润(净亏损以“-”号填列)                             8,069,611.90                          -4,059,561.32
    五、每股收益:                                       --                                     --
       (一)基本每股收益                                              0.06                                  -0.03
       (二)稀释每股收益                                              0.06                                  -0.03六、其他综合收益其中:以后会计期间不能重分类进损益的其他综合收益项目
         以后会计期间在满足规定条件时将重分类进损益的其他综合收益项目
    七、综合收益总额                                               8,069,611.90                          -4,059,561.32
    法定代表人:秦本军                       主管会计工作负责人:周庆伟                      会计机构负责人:张为鹏7、合并年初到报告期末现金流量表编制单位:桂林莱茵生物科技股份有限公司
                                                                                                          单位:元
                 项目                             本期金额                               上期金额一、经营活动产生的现金流量:
       销售商品、提供劳务收到的现金                          370,388,765.35                         171,453,573.68
       客户存款和同业存放款项净增加
                                    桂林莱茵生物科技股份有限公司 2014 年第三季度报告全文额
    向中央银行借款净增加额
    向其他金融机构拆入资金净增加额
    收到原保险合同保费取得的现金
    收到再保险业务现金净额
    保户储金及投资款净增加额
    处置交易性金融资产净增加额
    收取利息、手续费及佣金的现金
    拆入资金净增加额
    回购业务资金净增加额
    收到的税费返还                   6,314,238.14                          8,176,602.47
    收到其他与经营活动有关的现金     1,416,629.56                        219,387,640.51
    经营活动现金流入小计                378,119,633.05                        399,017,816.66
    购买商品、接受劳务支付的现金   272,773,894.43                        456,121,016.56
    客户贷款及垫款净增加额
    存放中央银行和同业款项净增加额
    支付原保险合同赔付款项的现金
    支付利息、手续费及佣金的现金
    支付保单红利的现金
    支付给职工以及为职工支付的现
                                     28,708,984.34                         21,887,756.28金
    支付的各项税费                   5,025,476.38                          1,923,892.75
    支付其他与经营活动有关的现金    25,702,838.84                         29,402,973.28
    经营活动现金流出小计                332,211,193.99                        509,335,638.87
    经营活动产生的现金流量净额           45,908,439.06                       -110,317,822.21二、投资活动产生的现金流量:
    收回投资收到的现金                                                    54,254,600.00
    取得投资收益所收到的现金         3,554,390.25                           251,335.13
    处置固定资产、无形资产和其他
                                      1,735,500.00长期资产收回的现金净额
    处置子公司及其他营业单位收到
                                     18,075,500.00的现金净额
    收到其他与投资活动有关的现金     1,650,000.00
                                                           桂林莱茵生物科技股份有限公司 2014 年第三季度报告全文
    投资活动现金流入小计                                        25,015,390.25                         54,505,935.13
       购建固定资产、无形资产和其他
                                                            27,667,631.07                         10,495,499.33长期资产支付的现金
       投资支付的现金                                        6,333,609.00
       质押贷款净增加额
       取得子公司及其他营业单位支付的现金净额
       支付其他与投资活动有关的现金
    投资活动现金流出小计                                        34,001,240.07                         10,495,499.33
    投资活动产生的现金流量净额                                   -8,985,849.82                        44,010,435.80三、筹资活动产生的现金流量:
       吸收投资收到的现金
       其中:子公司吸收少数股东投资收到的现金
       取得借款收到的现金                                   56,636,890.00                        364,251,529.92
       发行债券收到的现金
       收到其他与筹资活动有关的现金                         90,259,100.00                        392,145,400.00
    筹资活动现金流入小计                                       146,895,990.00                        756,396,929.92
       偿还债务支付的现金                                  133,490,926.15                        440,157,391.18
       分配股利、利润或偿付利息支付
                                                            26,713,113.06                         35,874,039.18的现金
       其中:子公司支付给少数股东的股利、利润
       支付其他与筹资活动有关的现金                         35,767,918.29                        233,712,029.98
    筹资活动现金流出小计                                       195,971,957.50                        709,743,460.34
    筹资活动产生的现金流量净额                                  -49,075,967.50                        46,653,469.58四、汇率变动对现金及现金等价物的
                                                               170,207.61                         -1,208,025.36影响
    五、现金及现金等价物净增加额                                -11,983,170.65                       -20,861,942.19
       加:期初现金及现金等价物余额                         38,680,937.10                         41,151,733.01
    六、期末现金及现金等价物余额                                26,697,766.45                         20,289,790.82
    法定代表人:秦本军                       主管会计工作负责人:周庆伟                    会计机构负责人:张为鹏8、母公司年初到报告期末现金流量表编制单位:桂林莱茵生物科技股份有限公司
                                               桂林莱茵生物科技股份有限公司 2014 年第三季度报告全文
                                                                                            单位:元
               项目                 本期金额                               上期金额一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金              223,150,567.61                         161,205,069.66
    收到的税费返还                              6,314,238.14                           8,176,602.47
    收到其他与经营活动有关的现金                  721,640.97                         214,718,461.09
    经营活动现金流入小计                           230,186,446.72                         384,100,133.22
    购买商品、接受劳务支付的现金              151,925,990.98                         382,860,738.47
    支付给职工以及为职工支付的现
                                                22,083,451.37                          16,098,865.50金
    支付的各项税费                              2,915,911.88                           1,568,860.59
    支付其他与经营活动有关的现金               16,307,484.84                          18,120,112.45
    经营活动现金流出小计                           193,232,839.07                         418,648,577.01
    经营活动产生的现金流量净额                      36,953,607.65                         -34,548,443.79二、投资活动产生的现金流量:
    收回投资收到的现金
    取得投资收益所收到的现金                    3,554,390.25                            251,335.13
    处置固定资产、无形资产和其他
                                                    35,500.00长期资产收回的现金净额
    处置子公司及其他营业单位收到
                                                18,075,500.00的现金净额
    收到其他与投资活动有关的现金                1,650,000.00
    投资活动现金流入小计                            23,315,390.25                            251,335.13
    购建固定资产、无形资产和其他
                                                27,478,888.02                           7,054,203.00长期资产支付的现金
    投资支付的现金                              6,333,609.00
    取得子公司及其他营业单位支付的现金净额
    支付其他与投资活动有关的现金
    投资活动现金流出小计                            33,812,497.02                           7,054,203.00
    投资活动产生的现金流量净额                      -10,497,106.77                         -6,802,867.87三、筹资活动产生的现金流量:
    吸收投资收到的现金
    取得借款收到的现金                         36,636,890.00                         149,251,529.92
    发行债券收到的现金
                                                        桂林莱茵生物科技股份有限公司 2014 年第三季度报告全文
       收到其他与筹资活动有关的现金                     101,000,000.00                        596,000,000.00
    筹资活动现金流入小计                                    137,636,890.00                        745,251,529.92
       偿还债务支付的现金                               123,490,926.15                        440,157,391.18
       分配股利、利润或偿付利息支付
                                                          4,777,389.27                         20,049,483.64的现金
       支付其他与筹资活动有关的现金                      57,999,266.07                        238,348,276.93
    筹资活动现金流出小计                                    186,267,581.49                        698,555,151.75
    筹资活动产生的现金流量净额                               -48,630,691.49                        46,696,378.17四、汇率变动对现金及现金等价物的
                                                            159,797.09                         -1,198,524.79影响
    五、现金及现金等价物净增加额                             -22,014,393.52                         4,146,541.72
       加:期初现金及现金等价物余额                      36,159,744.42                         10,785,342.58
    六、期末现金及现金等价物余额                             14,145,350.90                         14,931,884.30
    法定代表人:秦本军                    主管会计工作负责人:周庆伟                    会计机构负责人:张为鹏二、审计报告第三季度报告是否经过审计□ 是 √ 否
    公司第三季度报告未经审计。
                                                                          桂林莱茵生物科技股份有限公司
                                                                             法定代表人:______________
                                                                                                秦本军
                                                                                 二〇一四年十月二十八日
数据加载中...
prevnext
手机查看股票